Home  /   Products  /   Eye and ear  /   Travoprost-Optic eye drops 0.004% – [5 ml vial]

Travoprost-Optic eye drops 0.004% – [5 ml vial]


Antiglaucoma drug – a synthetic analogue of prostaglandin f2α

SKU: 62990 Category:


Travoprost-Optic Pharmacodynamics
Travoprost, a synthetic analog of prostaglandin F2?, is a highly selective full agonist of the prostaglandin receptor FP and decreases intraocular pressure by increasing aqueous outflow through the trabecular meshwork and uveoscleral pathways
Intraocular pressure decreases approximately 2 hours after application, and the maximum effect is achieved after 12 hours.
Significant decrease in intraocular pressure may persist for up to 24 hours after a single use of the drug.

Reduction of increased intraocular pressure in:
– open-angle glaucoma;
– Increased intraocular pressure

Hypersensitivity to the drug components, children under 18 years of age, pregnancy and breast-feeding.
The drug Travoprost-Optik should be used with caution in patients with aphakia; in patients with pseudo aphakia in case of rupture of the posterior lens capsule or in patients with an anterior chamber intraocular lens, in patients with the risk of cystoid macular edema.
Travoprost-Optik should be used with caution in patients with acute inflammatory phenomena of the visual organ, as well as in patients with risk factors predisposing to iritis, uveitis.
Usage during pregnancy and lactation
No studies have been conducted to evaluate the effect of the drug Travoprost-Optic on human fertility. Animal studies have shown that Travoprost has no effect on fertility when used in doses greater than 250 times the maximum recommended dose for humans.
There are no or limited data on the use of Travoprost-Optic in pregnant women. Animal studies with Travoprost have shown reproductive toxicity.

Directions for use and dosage

  • Topically. 1 drop into the conjunctival sac of the eye (eye) once a day, in the evening. To decrease the risk of systemic side effects it is recommended to squeeze the nasolacrimal duct after instillation of the drug by pressing on its projection at the inner corner of the eye.
  • If a dose of the drug was missed, treatment should be continued with the next dose. Daily dose should not exceed 1 drop in the conjunctival sac of the eye once a day
  • Travoprost-Optik may be used in combination with other topical ophthalmic drugs for reduction of intraocular pressure. In this case, the interval between their application should be at least 5 minutes.
  • If Travoprost-Optik is prescribed as a substitute for another ophthalmic drug for the treatment of glaucoma, the latter should be discontinued and Travoprost-Optik started the next day.